Document is current
Any future updates will be listed below
-
Authors
Chiu, May https://orcid.org/0000-0002-2062-8706
Schimmer, Aaron D. https://orcid.org/0000-0003-4023-3899
Schuh, Andre C.
Bankar, Aniket
Richard-Carpentier, Guillaume
Sibai, Hassan
Yee, Karen https://orcid.org/0000-0002-2572-9952
Davidson, Marta
Chan, Steven M.
Gupta, Vikas https://orcid.org/0000-0002-1419-8607
Maze, Dawn https://orcid.org/0000-0002-4598-9380
- License Information
-
More Information
Article History
Received: 18 July 2024
Revised: 3 October 2024
Accepted: 9 October 2024
First Online: 31 October 2024
Competing interests
: This study has not been funded by any pharmaceutical companies. There were no direct COI specifically related to this research project. ADS has received research funding from Takeda Pharmaceuticals, BMS, and Medivir AB, and consulting fees/honorarium from Takeda, Novartis, Jazz, and Otsuka Pharmaceuticals. ADS is named on a patent application for the use of DNT cells to treat AML. ADS is a member of the Medical and Scientific Advisory Board of the Leukemia and Lymphoma Society of Canada.
